Denosumab for Giant Cell Tumors of Bone from 2010 to 2022: a Bibliometric Analysis
Overview
Affiliations
Giant cell tumors of the bone (GCTB) are considered moderately malignant bone tumors. Denosumab, as a neoadjuvant therapy, provides new possibilities for treating GCTB. However, even after multiple studies and long-term clinical trials, there are limitations in the treatment process. Research data and Medical Subject Headings terms related to denosumab and GCTB were collected from January 2010 to October 2022 using the Web of Science and MeSH ( https://meshb.nlm.nih.gov ) browsers. These data were imported into CiteSpace and VOSviewer softwares for bibliometric analysis. Overall, 445 publications on denosumab and GCTB were identified. Over the last 12 years, the growth rate of the total number of publications has remained relatively stable. The USA published the highest number of articles (83) and had the highest centrality (0.42). Amgen Inc. and Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) First Ortoped Rizzoli were identified as the most influential institutions. Many authors have made outstanding contributions to this field. Lancet Oncology had the highest journal impact factor (54.433). Local recurrence and drug dosage are current research hotspots, and future development trends will mainly focus on prognostic markers of GCTB and the development of new therapies. Further research is required to analyze denosumab's safety and efficacy and understand its local recurrence of GCTB, to identify the optimal dose. Future progress in this field will likely focus on exploring new diagnostic and recurrence markers to monitor disease progression and examine new therapeutic targets and treatment strategies.
de la Calva C, Angulo M, Gonzalez-Rojo P, Peiro A, Machado P, Cebrian J Cancer Rep (Hoboken). 2025; 8(1):e70117.
PMID: 39797695 PMC: 11726647. DOI: 10.1002/cnr2.70117.
[One case of recurrent giant cell tumor of the larynx and literature review].
Liu Y, Xu K, Feng Q, Lu X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024; 38(11):1073-1076.
PMID: 39534902 PMC: 11879714. DOI: 10.13201/j.issn.2096-7993.2024.11.015.
Miao Z, Han Z, Zheng K, Xu M, Yu X, Han C Front Oncol. 2024; 14:1402550.
PMID: 39364313 PMC: 11446914. DOI: 10.3389/fonc.2024.1402550.
Xiang F, Zhang Y, Tan X, Zhang J, Li T, Yan Y Front Oncol. 2024; 14:1344643.
PMID: 38974238 PMC: 11224451. DOI: 10.3389/fonc.2024.1344643.
Giant Cell Tumor of the Inferior Turbinate in a 12-Year-Old Child: First Case Report.
Linxweiler M, Remke M, Straub B, Schick B OTO Open. 2024; 8(2):e165.
PMID: 38938508 PMC: 11208738. DOI: 10.1002/oto2.165.